The mechanisms of resistance to second- and third-generation ALK inhibitors and strategies to overcome such resistance

References

• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–566.
   PubMed Web of Science ®Google Scholar
• Collisson EA, Campbell JD, Brooks AN, et al. Comprehensive molecular profiling of lung adenocarcinoma: the cancer genome atlas research network. Nature. 2014;511:543–550.
   PubMed Web of Science ®Google Scholar
• Ou S-HI, Zhu VW, Nagasaka M. Catalog of 5ʹ Fusion Partners in ALK-positive NSCLC Circa 2020. JTO Clin Res Rep. 2020;1(1):100015.
   Google Scholar
• Dagogo-Jack I, Brannon AR, Ferris LA, et al. Tracking the evolution of resistance to ALK tyrosine kinase inhibitors through longitudinal analysis of circulating tumor DNA HHS public access. JCO Precis Oncol. 2018;(2):1–14. 10.1200/PO.17.00160.
   Google Scholar
• Gainor JF, Dardaei L, Yoda S, et al., Molecular mechanisms of resistance to first- and second-generation ALK Inhibitors in ALK-rearranged lung cancer. Cancer Discov. 6(10): 1118–1133. 2016.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer. N Engl J Med. 2013;368(25):2385–2394.
   PubMed Web of Science ®Google Scholar
• Lin JJ, Riely GJ, Shaw AT, et al. Precision medicine takes on drug resistance. Cancer Discovery. American Association for Cancer Research Inc.; 2017;7(2):137–155.
   Google Scholar
• Pao W, Girard N Review New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12(2):175-180. doi:10.1016/S1470-2045(10)70087-5 Available from: www.thelancet.com/oncologyVol12.
   Google Scholar
• Lin JJ, Zhu VW, Yoda S, et al. Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. J Clin Oncol Am Soc Clin Oncol. 2018;36(12):1199–1206.
   PubMed Web of Science ®Google Scholar
• Lee J-O, Kim TM, Lee S-H, et al. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol. 2011;6(9):1474–1480.
   PubMed Web of Science ®Google Scholar
• Recondo G, Mezquita L, Facchinetti F, et al. Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer. Clin Cancer Res. 2020;26(1):242–255.
   PubMed Web of Science ®Google Scholar
• Pailler E, Faugeroux V, Oulhen M, et al. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non–Small-Cell Lung Cancer. Clin Cancer Res. 2019;25(22):6671–6682.
   PubMed Web of Science ®Google Scholar
• Yoda S, Lin JJ, Lawrence MS, et al., Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. Cancer Discov. 8(6): 714–729. 2018.
   PubMed Web of Science ®Google Scholar
• Asao T, Fujiwara Y, Itahashi K, et al. Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non–Small-Cell Lung Cancer: a Retrospective Analysis. Clin Lung Cancer. 2017;18(4):e251–e258.
   PubMed Web of Science ®Google Scholar
• Gainor JF, Tan DSW, De Pas T, et al. Progression-free and overall survival in ALK-Positive NSCLC patients treated with sequential Crizotinib and Ceritinib. Clin Cancer Res. 2015;21(12):2745–2752.
   PubMed Web of Science ®Google Scholar
• Novello S, Mazières J, Oh IJ, et al. Alectinib versus chemotherapy in crizotinib pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018;29(6):1409–1416.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017;18(12):1590–1599.
   PubMed Web of Science ®Google Scholar
• Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer. N Engl J Med. 2018;379(21):2027–2039.
   PubMed Web of Science ®Google Scholar
• Lin JJ, Zhu VW, Schoenfeld AJ, et al. Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. J Thorac Oncol. 2018;13(10):1530–1538.
   PubMed Web of Science ®Google Scholar
• Kim D-W, Tiseo M, Ahn M-J, et al. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: a Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017;35(22):2490–2498.
   PubMed Web of Science ®Google Scholar
• Toyokawa G, Inamasu E, Shimamatsu S, et al. Identification of a novel ALK G1123S mutation in a patient with ALK-rearranged non-small-cell lung cancer exhibiting resistance to ceritinib. J Thorac Oncol. 2015;10(7):e55–e57.
   PubMed Web of Science ®Google Scholar
• Nishio M, Nakagawa K, Mitsudomi T. Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Lung Cancer. 2018;121:37–40.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654–1667.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Solomon BJ, Besse B, et al., ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer. J Clin Oncol. 2019;37(16):1370–1379.
   PubMed Web of Science ®Google Scholar
• Stinchcombe T, Doebele RC, Wang XF, et al. Preliminary results of single arm phase 2 trial of brigatinib in patients (pts) with progression disease (PD) after next-generation (NG) anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in ALK + non-small cell lung cancer (NSCLC). J clin oncol. 2019;37(15_suppl):9027.
   Web of Science ®Google Scholar
• Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol. 2013;14(7):590–598.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim TM, Crinò L, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18(7):874–886.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Kim D-W, Wu Y-L, et al. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer. J Clin Oncol. 2018;36(22):2251–2258.
   PubMed Web of Science ®Google Scholar
• Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer. N Engl J Med. 2017;377(9):829–838.
   PubMed Web of Science ®Google Scholar
• Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017;390(10089):29–39.
   PubMed Web of Science ®Google Scholar
• Kodama T, Tsukaguchi T, Yoshida M, et al. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett. 2014;351(2):215–221.
   PubMed Web of Science ®Google Scholar
• Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014;15(10):1119–1128.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Hayashi H, Okamoto K, et al. Progression-free and overall survival of patients with ALK rearrangement–positive non–small cell lung cancer treated sequentially with crizotinib and alectinib. Clin Lung Cancer. 2016;17(6):528–534.
   PubMed Web of Science ®Google Scholar
• Gadgeel S, Peters S, Mok T, et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALKþ) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol. 2018;29:2214–2222.
   PubMed Web of Science ®Google Scholar
• Ito K, Hataji O, Kobayashi H, et al. Sequential therapy with crizotinib and alectinib in ALK-rearranged non–small cell lung cancer—A multicenter retrospective study. J Thorac Oncol. 2017;12(2):390–396.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Friboulet L, Leshchiner I, et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med. 2016;374(1):54–61.
   PubMed Web of Science ®Google Scholar
• Katayama R, Friboulet L, Koike S, et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res. 2014;20(22):5686–5696.
   PubMed Web of Science ®Google Scholar
• Zhang S, Anjum R, Squillace R, et al. The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models. Clin Cancer Res. 2016;22(22):5527–5538.
   PubMed Web of Science ®Google Scholar
• Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non–small cell lung cancer. Cancer Discov. 2014;4(6):662–673.
   PubMed Web of Science ®Google Scholar
• Bazhenova L, Hodgson JG, Langer CJ, et al. Activity of brigatinib (BRG) in crizotinib (CRZ)-resistant ALK+ NSCLC patients (pts) according to ALK plasma mutation status. J clin oncol. 2017;35(15_suppl):9065.
   Google Scholar
• Recondo G, Facchinetti F, Olaussen KA, et al. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? Nature reviews clinical oncology. Nature Publishing Group; Nat Rev Clin Oncol. 2018;15(11):694-708. doi:10.1038/s41571-018-0081-4.
   Google Scholar
• Johnson TW, Richardson PF, Bailey S, et al. Discovery of (10 R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17- tetrahydro- 2H −8,4-(metheno)pyrazolo[4,3- h][2,5,11]- benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem. 2014;57(11):4720–4744.
   PubMed Web of Science ®Google Scholar
• Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389(10072):917–929.
   PubMed Web of Science ®Google Scholar
• Kimura M, Endo H, Inoue T, et al. Analysis of ERBB ligand-induced resistance mechanism to crizotinib by primary culture of lung adenocarcinoma with EML4-ALK fusion gene. J Thorac Oncol. 2015;10(3):527–530.
   PubMed Web of Science ®Google Scholar
• Toyokawa G, Seto T. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?. Clin Lung Cancer 2014;313–319. doi:10.1016/j.cllc.2014.05.001
   PubMedGoogle Scholar
• Gouji T, Takashi S, Mitsuhiro T, et al. Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor? J Thorac Oncol. 2014;9(3):e27–e28.
   PubMed Web of Science ®Google Scholar
• Toyokawa G, Hirai F, Inamasu E, et al. Secondary mutations at I1171 in the ALK gene confer resistance to both crizotinib and alectinib. J Thorac Oncol. 2014;9(12):e86–e87.
   PubMed Web of Science ®Google Scholar
• Dong X, Fernandez-Salas E, Li E, et al. Elucidation of resistance mechanisms to second-generation ALK inhibitors alectinib and ceritinib in non-small cell lung cancer cells. Neoplasia. 2016;18(3):162–171.
   PubMed Web of Science ®Google Scholar
• Ou S-HI, Azada M, Hsiang DJ. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol. 2014;9(4):549–553.
   PubMed Web of Science ®Google Scholar
• Mehlman C, Chaabane N, Lacave R, et al. Ceritinib ALK T1151R resistance mutation in lung cancer with initial response to brigatinib. J Thorac Oncol. 2019;14(5):e95–e96.
   PubMed Web of Science ®Google Scholar
• Katayama R. Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer. Cancer Science. Blackwell Publishing Ltd; Cancer Sci. 2018;109(3):572-580. doi:10.1111/cas.13504.
   Google Scholar
• Choi YL, Yamashita Y, Ueno T, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010;363(18):1734–1739.
   PubMed Web of Science ®Google Scholar
• Katayama R, Shaw AT, Khan TM, et al. Cancer: mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med. 2012;4(120):120ra17–120ra17.
   PubMed Web of Science ®Google Scholar
• Heuckmann JM, Hölzel M, Sos ML, et al. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res. 2011;17(23):7394–7401.
   PubMed Web of Science ®Google Scholar
• Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non–small cell lung cancer. Clin Cancer Res. 2012;18(5):1472–1482.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Okuda K, Zheng W, et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res. 2010;70(24):10038–10043.
   PubMed Web of Science ®Google Scholar
• Hrustanovic G, Olivas V, Pazarentzos E, et al. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015;21(9):1038–1047.
   PubMed Web of Science ®Google Scholar
• Crystal AS, Shaw AT, Sequist LV, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science. 2014;346(6216):1480–1486. Available from.
   PubMed Web of Science ®Google Scholar
• Tricker EM, Xu C, Uddin S, et al. Combined EGFR/MEK inhibition prevents the emergence of resistance in EGFR-mutant lung cancer. Cancer Discov. 2015;5(9):960–971.
   PubMed Web of Science ®Google Scholar
• Tanizaki J, Okamoto I, Okabe T, et al. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Clin Cancer Res. 2012;18(22):6219–6226.
   PubMed Web of Science ®Google Scholar
• Camidge DR, Doebele RC. Treating ALK-positive lung cancer-early successes and future challenges. Nat Rev Clin Oncol. 2012;9(5):268–277.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26–75ra26.
   PubMed Web of Science ®Google Scholar
• Cha YJ, Cho BC, Kim HR, et al. A case of ALK-rearranged adenocarcinoma with small cell carcinoma-like transformation and resistance to crizotinib. J Thorac Oncol. 2016;11(5):e55–e58.
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Sakao Y, Ito S, et al. Transformation to Sarcomatoid Carcinoma in ALK-rearranged adenocarcinoma, which developed acquired resistance to crizotinib and received subsequent chemotherapies. J Thorac Oncol. 2013;8(8):e75–e78. Available from.
   PubMed Web of Science ®Google Scholar
• Gower A, Hsu W-H, Hsu S-T, et al. EMT is associated with, but does not drive resistance to ALK inhibitors among EML4-ALK non-small cell lung cancer. Mol Oncol. 2016;10(4):601–609.
   PubMed Web of Science ®Google Scholar
• Fukuda K, Takeuchi S, Arai S, et al. Epithelial-to-mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK mutation status. Cancer Res. 2019;79(7):1658–1670.
   PubMed Web of Science ®Google Scholar
• Sakamoto H, Tsukaguchi T, Hiroshima S, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011;19(5):679–690.
   PubMed Web of Science ®Google Scholar
• Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31(8):1056–1064.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Koivunen J, Ogino A, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011;71(18):6051–6060.
   PubMed Web of Science ®Google Scholar
• Noé J, Lovejoy A, Ou SHI, et al. ALK mutation status before and after alectinib treatment in locally advanced or metastatic ALK-positive NSCLC: pooled analysis of two prospective trials. J Thorac Oncol. 2020;15(4):601–608.
   PubMed Web of Science ®Google Scholar
• Isozaki H, Ichihara E, Takigawa N, et al. Non-small cell lung cancer cells acquire resistance to the ALK inhibitor alectinib by activating alternative receptor tyrosine kinases. Cancer Res. 2016;76(6):1506–1516.
   PubMed Web of Science ®Google Scholar
• Tanimoto A, Yamada T, Nanjo S, et al. Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. Oncotarget. 2014;5(13):4920–4928. Available from.
   Google Scholar
• Makimoto G, Ohashi K, Tomida S, et al. Rapid acquisition of alectinib resistance in ALK-positive lung cancer with high tumor mutation burden. J Thorac Oncol. 2019;14(11):2009–2018.
   PubMed Web of Science ®Google Scholar
• Attili I, Bonanno L, Karachaliou N. SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer. Transl Lung Cancer Res. 2020;9(5):1810–1821.
   PubMed Web of Science ®Google Scholar
• Tsuji T, Ozasa H, Aoki W, et al. Alectinib resistance in ALK-rearranged lung cancer by dual salvage signaling in a clinically paired resistance model. Mol Cancer Res. 2019;17(1):212–224.
   PubMed Web of Science ®Google Scholar
• Moroishi T, Hansen CG, Guan K-L. The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 2015;15(2):73–79.
   PubMed Web of Science ®Google Scholar
• Tsuji T, Ozasa H, Aoki W, et al. YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation. Nat Commun. 2020;11(1). 10.1038/s41467-019-13771-5.
   Web of Science ®Google Scholar
• Arai S, Takeuchi S, Fukuda K, et al. Osimertinib overcomes alectinib resistance caused by amphiregulin in a leptomeningeal carcinomatosis model of ALK-rearranged lung cancer. J Thorac Oncol. 2020;15(5):752–765.
   PubMed Web of Science ®Google Scholar
• Funazo TY, Tsuji T, Ozasa H, et al. Acquired resistance to alectinib in ALK-rearranged lung cancer due to ABCC11/MRP8 overexpression in a clinically paired resistance model. Mol Cancer Ther. Mol Cancer Ther. 2020;19(6):1320-1327. doi:10.1158/1535-7163.MCT-19-0649.
   Web of Science ®Google Scholar
• Fujita S, Masago K, Katakami N, et al. Transformation to SCLC after treatment with the ALK inhibitor alectinib. J Thorac Oncol. 2016;11(6):e67–e72.
   PubMed Web of Science ®Google Scholar
• Marsilje TH, Pei W, Chen B, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro- N 2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)- N 4-(2-(isopropylsulfonyl) phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013;56(14):5675–5690.
   PubMed Web of Science ®Google Scholar
• Cho BC, Kim DW, Bearz A, et al. ASCEND-8: a randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non–small cell lung cancer (NSCLC). J Thorac Oncol. 2017;12(9):1357–1367.
   PubMed Web of Science ®Google Scholar
• Katayama R, Khan TM, Benes C, et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A. 2011;108(18):7535–7540.
   PubMed Web of Science ®Google Scholar
• Katayama R, Sakashita T, Yanagitani N, et al. P-glycoprotein mediates ceritinib resistance in anaplastic lymphoma kinase-rearranged non-small cell lung cancer. EBioMedicine. 2016;3:54–66.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Yang Y, Xu Y, et al. AZD0530 sensitizes drug-resistant ALK-positive lung cancer cells by inhibiting SRC signaling. FEBS Open Bio. 2017;7(4):472–476.
   PubMed Web of Science ®Google Scholar
• Dardaei L, Wang HQ, Singh M, et al. SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. Nat Med. 2018;24(4):512–517.
   PubMed Web of Science ®Google Scholar
• Lovly CM, McDonald NT, Chen H, et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat Med. 2014;20(9):1027–1034.
   PubMed Web of Science ®Google Scholar
• Camidge R, Kim HR, Ahn M-J, et al. Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: updated results from the phase III ALTA-1L trial. Ann Oncol. 2019;30:ix195–ix196.
   Google Scholar
• Vojnic M, Kubota D, Kurzatkowski C, et al. Acquired BRAF rearrangements induce secondary resistance to EGFR therapy in EGFR-mutated lung cancers. J Thorac Oncol. 2019;14(5):802–815.
   PubMed Web of Science ®Google Scholar
• Ohashi K, Sequist LV, Arcila ME, et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A. 2012;109(31):E2127–33.
   PubMed Web of Science ®Google Scholar
• Selvaggi G, Wakelee HA, Mok T, et al. Phase III randomized study of ensartinib vs crizotinib in anaplastic lymphoma kinase (ALK) positive NSCLC patients: eXalt3. J Thorac Oncol. 2020;15S:IASLC #1882.
   Google Scholar
• Akamine T, Toyokawa G, Tagawa T, et al. Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date. OncoTargets and therapy. Dove Medical Press Ltd; Onco Targets Ther. 2018;11:5093-5101. Published 2018 Aug 22. doi:10.2147/OTT.S165511.
   Google Scholar
• Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018–2029.
   PubMed Web of Science ®Google Scholar
• Mizuta H, Okada K, Araki M, et al. Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer. Nat Commun. 2021;12(1):1261.
   PubMed Web of Science ®Google Scholar
• Redaelli S, Ceccon M, Zappa M, et al. Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer. Cancer Res. 2018;78(24):6866–6880.
   PubMed Web of Science ®Google Scholar
• Kron A, Alidousty C, Scheffler M, et al. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann Oncol. 2018;29(10):2068–2075.
   PubMed Web of Science ®Google Scholar
• Hainaut P, Pfeifer GP. Somatic TP53 mutations in the era of genome sequencing. Cold Spring Harb Perspect Med. 2016;6(11):a026179.
   PubMed Web of Science ®Google Scholar
• Petrilli AM, Fernández-Valle C. Role of Merlin/NF2 inactivation in tumor biology. Oncogene. 2016;35(5):537–548.
   PubMed Web of Science ®Google Scholar
• Coleman N, Wotherspoon A, Yousaf N, et al. Transformation to neuroendocrine carcinoma as a resistance mechanism to lorlatinib. Lung Cancer. 2019;134:117–120.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639.
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial [published correction appears in Lancet. 2017 Apr 8;389(10077):e5]. Lancet. 2017;389(10066):255–265.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550.
   PubMed Web of Science ®Google Scholar
• Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;30(8):1321–1328.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Lee SH, Ramalingam SS, et al. Avelumab (anti-PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: phase 1b results from JAVELIN Lung 101. J Clin Oncol. 2018;36(15_suppl):9008.
   Web of Science ®Google Scholar
• Wang L, Lui VWY. Emerging roles of ALK in immunity and insights for immunotherapy. Cancers (Basel). 2020;12(2):426.
   Web of Science ®Google Scholar
• Haratake N, Seto T, Takamori S, et al. Short progression-free survival of ALK inhibitors sensitive to secondary mutations in ALK-positive NSCLC patients. Thorac Cancer. 2019;10(9):1779–1787.
   PubMed Web of Science ®Google Scholar
• Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446–451.
   PubMed Web of Science ®Google Scholar
• Jonsson VD, Blakely CM, Lin L, et al., Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution. Sci Rep. 7(1): 44206. 2017.
   PubMedGoogle Scholar
• Iwama E, Sakai K, Hidaka N, et al. Longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor-tyrosine kinase inhibitors. Cancer. 2020;126(1):219–227.
   PubMed Web of Science ®Google Scholar
• Horn L, Whisenant JG, Wakelee H, et al. Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer. J Thorac Oncol. 2019;14(11):1901–1911.
   PubMed Web of Science ®Google Scholar